65,437 trials
Immunization Status · Well Child Care Visit
Primary: Fully Vaccinated (Tdap, Menactra and 3 Doses of HPV (if Female)) — 143; 160; 100 participants — p=<0.05
Osteoporosis · Postmenopausal Osteoporosis
Primary: Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD) — -0.36; -0.67; -0.52; -0.53 percent change — p=0.012
Phenylketonuria
Primary: Tabulation of the Incidence and Frequency of All AEs and SAEs That Occur Throughout the Study. — 83.8; 33.3; 6.3; 0.9 percentage of subjects reporting events
Lung Cancer
Primary: Interleukin Levels at 24 Hours — 245; 269; 11.3; 14.8 pg/ml — p=0.39
Conjunctival Staining
Primary: Mean Circumlimbal Conjunctival Staining Score — 6.39; 5.55; 5.68 Units on a scale
Uterine Myomas
Primary: Co-primary Endpoint: Percentage of Subjects With Reduction in Uterine Bleeding Defined as a Pictorial Blood-loss Assessment Chart (PBAC) Score <75 at End-of-treatment…
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) — 71.5; 70.9 percentage of participants
Cervical Intraepithelial Neoplasia
Primary: Endocervical Margin Not Free of Disease. — 8; 10 participants
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
HIV Infections · Hyperlipidemia
Primary: Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval — 1.09; 1.59; 1.75 ng*hr/ml — p=0.43
Endogenous Anterior Uveitis
Primary: Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14 — 2.6; 2.6; -2.2; -2.0 Units on a scale
Parkinson Disease
Primary: Gait Speed — 8.35; 8.41; 25.84; 8.80 seconds
Binge Eating · Depression
Primary: Binge Eating Days — 4.3; 3.8 Mean Number of days — p=<0.05
Thymoma · Thymic Carcinoma · Thymic Carcinoid
Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…
Prostatic Neoplasms
Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants